Insider Transactions in Q4 2025 at Biocryst Pharmaceuticals Inc (BCRX)
Insider Transaction List (Q4 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 22
2025
|
Alane P Barnes Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
21,773
-5.18%
|
$152,411
$7.65 P/Share
|
|
Dec 22
2025
|
Charles K Gayer President and CCO |
BUY
Exercise of conversion of derivative security
|
Direct |
74,233
+2.55%
|
$296,932
$4.59 P/Share
|
|
Dec 19
2025
|
Alane P Barnes Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
16,902
-3.86%
|
$118,314
$7.41 P/Share
|
|
Dec 19
2025
|
Jon P Stonehouse Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
61,793
-4.46%
|
$432,551
$7.41 P/Share
|
|
Dec 19
2025
|
Charles K Gayer President and CCO |
SELL
Payment of exercise price or tax liability
|
Direct |
11,477
-1.29%
|
$80,339
$7.41 P/Share
|
|
Dec 18
2025
|
Jon P Stonehouse Chief Executive Officer |
BUY
Bona fide gift
|
Indirect |
20,000
+20.0%
|
-
|
|
Dec 18
2025
|
Jon P Stonehouse Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
20,000
-1.42%
|
-
|
|
Dec 17
2025
|
Charles K Gayer President and CCO |
BUY
Grant, award, or other acquisition
|
Direct |
471,000
+34.61%
|
-
|
|
Dec 17
2025
|
Alane P Barnes Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
121,700
+21.77%
|
-
|
|
Dec 17
2025
|
Babar Ghias Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
121,700
+31.17%
|
-
|
|
Dec 15
2025
|
Alane P Barnes Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
21,210
-6.3%
|
$148,470
$7.65 P/Share
|
|
Dec 12
2025
|
Charles K Gayer President and CCO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,181
-1.92%
|
$57,267
$7.57 P/Share
|
|
Dec 12
2025
|
Alane P Barnes Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,540
-2.47%
|
$59,780
$7.57 P/Share
|
|
Dec 12
2025
|
Jon P Stonehouse Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
27,368
-1.91%
|
$191,576
$7.57 P/Share
|
|
Dec 03
2025
|
Alane P Barnes Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
19,770
-5.41%
|
$138,390
$7.65 P/Share
|
|
Dec 02
2025
|
Alane P Barnes Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
50,906
-12.23%
|
$356,342
$7.21 P/Share
|
|
Dec 01
2025
|
Alane P Barnes Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
91,004
-17.94%
|
$637,028
$7.1 P/Share
|
|
Dec 01
2025
|
Alane P Barnes Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
91,004
+15.21%
|
$273,012
$3.22 P/Share
|
|
Nov 28
2025
|
Steven Frank Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,566
+8.16%
|
$10,962
$7.18 P/Share
|
|
Nov 28
2025
|
Amy E Mc Kee Director |
BUY
Grant, award, or other acquisition
|
Direct |
783
+1.84%
|
$5,481
$7.18 P/Share
|
|
Nov 28
2025
|
Vincent Milano Director |
BUY
Grant, award, or other acquisition
|
Direct |
783
+0.85%
|
$5,481
$7.18 P/Share
|
|
Nov 13
2025
|
Machelle Sanders Director |
SELL
Open market or private sale
|
Direct |
9,600
-23.86%
|
$67,200
$7.14 P/Share
|